Hematopoietic stem cell transplantation and implications for cell therapy reimbursement

Richard T. Maziarz; Dawn Driscoll

doi:10.1016/j.stem.2011.05.013

Hematopoietic stem cell transplantation and implications for cell therapy reimbursement

Richard T. Maziarz, Dawn Driscoll

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

11 Scopus citations

Abstract

As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.

Original language	English (US)
Pages (from-to)	609-612
Number of pages	4
Journal	Cell Stem Cell
Volume	8
Issue number	6
DOIs	https://doi.org/10.1016/j.stem.2011.05.013
State	Published - Jun 3 2011

ASJC Scopus subject areas

Molecular Medicine
Genetics
Cell Biology

Access to Document

10.1016/j.stem.2011.05.013

Cite this

@article{6ff6fc47307042a78b9b091ed4207761,

title = "Hematopoietic stem cell transplantation and implications for cell therapy reimbursement",

abstract = "As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.",

author = "Maziarz, {Richard T.} and Dawn Driscoll",

year = "2011",

month = jun,

day = "3",

doi = "10.1016/j.stem.2011.05.013",

language = "English (US)",

volume = "8",

pages = "609--612",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation and implications for cell therapy reimbursement

AU - Maziarz, Richard T.

AU - Driscoll, Dawn

PY - 2011/6/3

Y1 - 2011/6/3

N2 - As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.

AB - As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.

UR - http://www.scopus.com/inward/record.url?scp=79957801289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957801289&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2011.05.013

DO - 10.1016/j.stem.2011.05.013

M3 - Comment/debate

C2 - 21624804

AN - SCOPUS:79957801289

SN - 1934-5909

VL - 8

SP - 609

EP - 612

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 6

ER -

Hematopoietic stem cell transplantation and implications for cell therapy reimbursement

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this